DALLAS, October 21, 2014 /PRNewswire/ --
ReportsnReports.com adds China Heparin Industry Report, 2014-2017 market research to its store that says in terms of the proposed/ongoing projects, it is projected that the heparin API in China will achieve an additional capacity of more than 20 trillion units by 2015, when China's total capacity will exceed 30 trillion units, accounting for roughly 80% of the global demand. Complete report is available at http://www.reportsnreports.com/reports/312048-china-heparin-industry-report-2014-2017.html .
As the world's major heparin API producer and exporter, China boasts enormous raw materials, which provides a strong support for the production of China's heparin products. In 2013, the live pigs raised in China could manufacture 27.9 trillion units of heparin crude products. And in H1 2014, the live hogs in China may produce 14.09 trillion units of heparin crude products, up 5.6% on a year-on-year basis.
In 2011-2013, affected by the economic downturn in Europe and America, the global heparin preparations market continued to drop, with the sales volume of main heparin preparations brands virtually presenting decline, thus dragging down the exports of China's heparin products. In 2013, China exported approximately 13.68 trillion units of heparin and its salts, falling 5.9% year on year, and the figure edged down 0.6% from a year earlier to around 9.32 trillion units in Jan.-Aug. 2014.
The major global heparin API suppliers, including Hepalink, Nanjing King-friend, Dongcheng Biochemicals, Qianhong Bio-pharma, and Changshan Biochemical Pharmaceutical, have been among the top 4 heparin exporters in China for many years, together accounting for over 60% of China's total heparin exports. In response to the impact from international markets, enterprises are stepping up efforts to figure out the solutions, with Hepalink expanding its market share of heparin crude products via M&As overseas. By contrast, the enterprises like Qianhong Bio-pharma, Dongcheng Biochemicals, and Changshan Biochemical Pharmaceutical have accelerated the R&D into and production of low molecular weight heparin preparations. And Nanjing King-friend is aggressively seeking to expand capacity through IPO.
China Heparin Market Companies profiled in this research include Hepalink, Qianhong Bio-pharma, Dongcheng Biochemicals, Changshan Biochemical Pharmaceutical, Tianjin Chase Sun Pharmaceutical, Nanjing King-friend and Wanbang Biopharmaceuticals. Order a copy of this report at http://www.reportsnreports.com/Purchase.aspx?name=312048 .
Although the leading heparin enterprises planned to increase capacity and improve the heparin industry chain a few years ago, yet quite a few heparin API projects that had been scheduled to go into operation in 2014 were delayed successively due to depressed market demand or improved technical standards, these projects including Dongcheng Biochemicals' 32t/a Crude Heparin Sodium Project and Qianhong Bio-pharma's Heparin API and Preparations Expansion Project.
Given that America's economy showed signs of recovery and the European economy did not continue to deteriorate, we foresee that the market size of the global heparin API and preparation market will bounce back in 2014-2017, when China's heparin industry, heparin API in particular, will see an improved degree of prosperity, thus further releasing new capacity.
The China Heparin Industry Report, 2014-2017 mainly deals with: Global heparin supply & demand, competitive landscape and forecast, etc.; Development, access barriers, supply & demand, competitive landscape, import & export, and development forecast, etc. of China heparin API industry; Development, supply & demand, competitive landscape and development forecast, etc. of China heparin preparations industry; Operation, Heparin Business, development prospect, etc. of 7 heparin enterprises, including Hepalink Nanjing King-friend, Qianhong Bio-pharma, Dongcheng Biochemicals, as well as Changshan Biochemical Pharmaceutical.
Partial list of charts provided in this Chinese heparin market report for 2014-2017 include:
Chinese Heparin Preparation Market Size and YoY Growth, 2014-2017E
Assets, Revenue and Profit of Hepalink's Major Subsidiaries, 2014H1
Revenue and Net Income of Hepalink, 2014-2017E
Operating Revenue Structure of Qianhong Bio-pharma by Product, 2014H1
Assets, Revenue and Net Income of Qianhong Bio-pharma's Subsidiaries, 2014H1
Gross Margin of Qianhong Bio-pharma's Heparin Products, 2008-2013
Revenue and Net Income of Qianhong Bio-pharma, 2014-2017E
Revenue and Net Income of Dongcheng Biochemicals, 2014-2017E
Revenue and Profit of Changshan Biochemical, 2008-2014
Operating Revenue Structure of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Revenue Breakdown of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Operating Revenue Structure of Changshan Biochemical Pharmaceutical by Product, 2008-2014
Revenue Breakdown of Changshan Biochemical Pharmaceutical by Product, 2008-2014
Consolidated Gross Margin of Changshan Biochemical Pharmaceutical, 2008-2014
Gross Margin of Changshan Biochemical Pharmaceutical by Region, 2008-2014
Gross Margin of Changshan Biochemical Pharmaceutical by Product, 2008-2014
R&D Costs and % of Total Revenue of Changshan Biochemical Pharmaceutical, 2009-2014
Progress of Changshan Biochemical Pharmaceutical's Products under Research as of Jun. 2014
Changshan Biochemical Pharmaceutical's Revenue from Top 5 Clients and % of Total Revenue, 2009-2014
Output, Sales Volume and Inventory of Changshan Biochemical Pharmaceutical's Heparin Sodium API and Its Preparations, 2011-2014
Revenue and Net Income of Changshan Biochemical Pharmaceutical, 2014-2017E
Another business intelligence study titled Market Research Report on Global and Chinese Heparin (CAS 9005-49-6) Industry, 2009-2019 reviews the basic information of Heparin including its classification, application and manufacturing technology; The report then explores global and China's top manufacturers of Heparin listing their product specification, capacity, Production value, and market share etc.; The report further analyzes quantitatively 2009-2014 global and China's total market of Heparin by calculation of main economic parameters of each company; The breakdown data of Heparin market are presented by company, by country, and by application; The report also estimates 2014-2019 market development of Heparin Industry. The report then analyzes the upstream raw materials, downstream clients, and current market dynamics of Heparin Industry. In the end, the report makes some proposals for a new project of Heparin Industry and a new project of Heparin Industry before evaluating its feasibility. Overall, the report provides an in-depth insight of 2009-2014 global and China Heparin industry covering all important parameters. Comprehensive Table of Contents and more on this report is available at http://www.reportsnreports.com/reports/295925-market-research-report-on-global-and-chinese-heparin-cas-9005-49-6-industry-2009-2019.html .
Explore more reports on pharmaceuticals market at http://www.reportsnreports.com/market-research/pharmaceuticals/ .
ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Connect With Us on:
Twitter: https: //twitter.com/marketsreports